Figure 2: Activation of ARF and loss-of-function mutation in ERAS regulate tumour resistance of NMR-iPSCs. | Nature Communications

Figure 2: Activation of ARF and loss-of-function mutation in ERAS regulate tumour resistance of NMR-iPSCs.

From: Tumour resistance in induced pluripotent stem cells derived from naked mole-rats

Figure 2

(a) The qRT–PCR analysis of the expression of INK4a, ARF, INK4b and p21 in NMR- and Ms-iPSCs (n=3 clones). The data are represented as mean±s.e.m. (b) Alignment of the coding sequences of ERAS of 11 species. DMR, damaraland mole-rat; BMR, blind mole-rat. (c,d) Teratoma formation. shN.C.-, shARF-, mERas- or shARF/mERas-expressing NMR-iPSCs were transplanted into the testes of NOD/SCID mice. Representative tumours 10 weeks after transplantation (c). Tumour weights (d). n=8 (shN.C., 10 weeks; shN.C., 20 weeks; mERas, 10 weeks; shARF, 10 weeks; shARF/mERas, 10 weeks), n=10 (shARF/mERas, 20 weeks) and n=16 (mERas, 20 weeks; shARF, 20 weeks). n: number of transplanted testes. The data are represented as mean±s.e.m. Y axis: weights in 6+log2 arbitrary units. *P<0.05; NS, not significant, Kruskal–Wallis followed by Dunn’s test.

Back to article page